ATE486059T1 - Synthese und verfahren zu deren verwendung von tetrahydroindolon analogen und derivaten - Google Patents

Synthese und verfahren zu deren verwendung von tetrahydroindolon analogen und derivaten

Info

Publication number
ATE486059T1
ATE486059T1 AT02725584T AT02725584T ATE486059T1 AT E486059 T1 ATE486059 T1 AT E486059T1 AT 02725584 T AT02725584 T AT 02725584T AT 02725584 T AT02725584 T AT 02725584T AT E486059 T1 ATE486059 T1 AT E486059T1
Authority
AT
Austria
Prior art keywords
derivatives
synthesis
analogues
tetrahydroindolone
tetrahydroindolone analogues
Prior art date
Application number
AT02725584T
Other languages
English (en)
Inventor
David Fick
Mark Foreman
Alvin Glasky
Original Assignee
Spectrum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals Inc filed Critical Spectrum Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE486059T1 publication Critical patent/ATE486059T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
AT02725584T 2001-04-20 2002-04-08 Synthese und verfahren zu deren verwendung von tetrahydroindolon analogen und derivaten ATE486059T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/839,289 US6759427B2 (en) 2001-04-20 2001-04-20 Synthesis and methods of use of tetrahydroindolone analogues and derivatives
PCT/US2002/011142 WO2002085856A1 (en) 2001-04-20 2002-04-08 Synthesis and methods of use of tetrahydroindolone analogues and derivatives

Publications (1)

Publication Number Publication Date
ATE486059T1 true ATE486059T1 (de) 2010-11-15

Family

ID=25279337

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02725584T ATE486059T1 (de) 2001-04-20 2002-04-08 Synthese und verfahren zu deren verwendung von tetrahydroindolon analogen und derivaten

Country Status (7)

Country Link
US (6) US6759427B2 (de)
EP (1) EP1383742B1 (de)
AT (1) ATE486059T1 (de)
DE (1) DE60238113D1 (de)
DK (1) DK1383742T3 (de)
ES (1) ES2385932T3 (de)
WO (1) WO2002085856A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759427B2 (en) * 2001-04-20 2004-07-06 Spectrum Pharmaceuticals, Inc. Synthesis and methods of use of tetrahydroindolone analogues and derivatives
JP4964593B2 (ja) * 2003-09-25 2012-07-04 セノメド バイオサイエンシーズ，エルエルシー 神経学的病状の治療用のテトラヒドロインドロン誘導体
US20050107439A1 (en) * 2003-11-10 2005-05-19 Helton David R. Composition and method for treating emesis
WO2006133634A1 (en) * 2005-06-14 2006-12-21 Beijing Gylongly Biodemtech Co., Ltd Tetrahydroindole derivatives and tetrahydroindazole derivatives, and use thereof
CA2642931A1 (en) * 2006-02-27 2007-09-07 Serenex, Inc. Cyclohexylamino, benzene, pyridine, and pyridazine derivatives
SI2089417T1 (sl) 2006-10-12 2015-04-30 Bhi Limited Partnership Metode, spojine, sestavki in vektorji za dostavo 3-amino-1-propansulfonske kisline
WO2009062134A1 (en) * 2007-11-09 2009-05-14 Cenomed Biosciences, Llc Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperazine compounds
US20090264443A1 (en) * 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
CA2762528A1 (en) * 2009-05-29 2010-12-02 Astellas Pharma Inc. Novel pharmaceutical composition for prevention and/or treatment of attention deficit/hyperactivity disorder
RU2503452C2 (ru) * 2011-11-24 2014-01-10 Общество С Ограниченной Ответственностью "Консорциум-Пик" Фармацевтическая композиция на основе растительной докозагексаеновой кислоты для профилактики синдрома гиперактивности у детей
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
CN120820389A (zh) 2016-04-22 2025-10-21 贝克顿·迪金森公司 多重聚合染料装置及其使用方法
JP7058662B2 (ja) 2017-02-08 2022-04-22 ベクトン・ディキンソン・アンド・カンパニー 乾燥色素試薬装置、ならびにその製造及び使用方法
US11992844B2 (en) 2018-11-13 2024-05-28 Becton, Dickinson And Company Dried reagent strainers and methods for making and using the same
WO2021138540A1 (en) 2020-01-03 2021-07-08 Berg Llc Polycyclic amides as ube2k modulators for treating cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3300380A (en) 1963-12-26 1967-01-24 Upjohn Co Diminishing toxicity of antiviral nu6-(hydroxyalkyl) adenines with 4-hydroxypyrazolo(3, 4-d) pyrimidine
US3321369A (en) 1965-05-26 1967-05-23 Abbott Lab Method of enhancing learning rate and retention level in warm blooded animals
US3438968A (en) 1966-06-23 1969-04-15 Int Chem & Nuclear Corp Substituted ammonium basic addition salts of ribonucleic acid
BE759011A (fr) 1969-11-17 1971-05-17 Wellcome Found Aminopurines
DE2554453A1 (de) 1974-12-18 1976-06-24 Experimentales Et Cliniques De Medikament zur glykaemieregulierung
GB1530912A (en) 1975-02-13 1978-11-01 Wellcome Found Compositions containing 9-(2-hydroxy-3-alkyl)-adenines
US4138562A (en) 1977-02-09 1979-02-06 The Regents Of The University Of Minnesota Adenosine deaminase resistant antiviral purine nucleosides and method of preparation
US4221910A (en) 1978-09-15 1980-09-09 Newport Pharmaceuticals International, Inc. 9-(Hydroxy alkyl)purines
US4221909A (en) 1978-09-15 1980-09-09 Sloan-Kettering Institute For Cancer Research P-Acetamidobenzoic acid salts of 9-(hydroxyalkyl) purines
US4221794A (en) 1979-06-21 1980-09-09 Newport Pharmaceuticals International, Inc. Method of imparting immunomodulating and antiviral activity
US4340726A (en) 1980-03-14 1982-07-20 Newport Pharmaceuticals International, Inc. Esters
US4347360A (en) 1980-09-16 1982-08-31 Ens Bio Logicals Inc. Ring open nucleoside analogues
US4451478A (en) 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
US4977178A (en) * 1982-09-20 1990-12-11 Pfizer Inc. Method of treating anxiety and depression with 1-phenyl-2(1H,3H)-indolone psycho-therapeutic agents
US4643992A (en) 1982-11-09 1987-02-17 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US5093318A (en) 1983-11-01 1992-03-03 Scripps Clinic And Research Foundation Immunostimulating guanosine derivatives and their pharmaceutical compositions
US4952693A (en) 1984-10-12 1990-08-28 Warner-Lambert Company Oxazolo-pyrimidine derivatives
JPH0696534B2 (ja) 1986-04-25 1994-11-30 ヘキストジヤパン株式会社 抗痴呆剤
US5495010A (en) 1987-04-17 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services Acid stable purine dideoxynucleosides
ES2091186T3 (es) 1988-04-19 1996-11-01 Pasteur Institut Procedimiento para obtener antigenos protectores contra infecciones y procesos toxicos de bordetella.
US5256677A (en) 1989-05-23 1993-10-26 Abbott Laboratories Retroviral protease inhibiting compounds
FI921092A7 (fi) 1989-09-15 1992-03-13 Gensia Pharma Menetelmä neurodegeneratiivisten tilojen hoitamiseksi
US5026687A (en) 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
US5091432A (en) 1990-03-28 1992-02-25 Glasky Alvin J 9-substituted hypoxanthine bi-functional compounds and their neuroimmunological methods of use
US5237051A (en) 1990-12-06 1993-08-17 Vanderbilt University Purified enterotoxin receptor protein
US5319096A (en) 1992-04-03 1994-06-07 Hoechst-Roussel Pharmaceuticals Inc. (1H-indol-1-yl)-2-(amino) acetamides and related (1H-indol-1-yl)-(aminoalkyl)amides, pharmaceutical composition and use
US5801184A (en) 1994-07-25 1998-09-01 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
US5447939A (en) 1994-07-25 1995-09-05 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
US5644568A (en) * 1995-03-15 1997-07-01 Motorola, Inc. Method and apparatus for organizing and recovering information communicated in a radio communication system
FR2736640B1 (fr) * 1995-07-13 1997-08-22 Oreal Compositions de teinture des fibres keratiniques contenant des derives n-substitues du 4-hydroxy indole, nouveaux derives, leur procede de synthese, leur utilisation pour la teinture, et procede de teinture
JP2842816B2 (ja) * 1995-10-16 1999-01-06 日本電気アイシーマイコンシステム株式会社 半導体記憶装置
US5795756A (en) 1995-12-11 1998-08-18 Johnson; Roger A. Method and compounds for the inhibition of adenylyl cyclase
US5948771A (en) 1996-01-31 1999-09-07 The Trustees Of Columbia University In The City Of New York Method for treating heart failure using tetrapyrroles and metallotetrapyrroles
US5801159A (en) 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
AU3785799A (en) 1998-05-04 1999-11-23 Neotherapeutics, Inc. Method for treating migraine in mammals
US6303617B1 (en) 1998-05-04 2001-10-16 Neotherapeutics, Inc. Serotonin-like 9-substituted hypoxanthine and methods of use
AU3879899A (en) 1998-05-04 1999-11-23 Neotherapeutics, Inc. Novel dopamine-like 9-substituted hypoxanthine and methods of use
GB9812038D0 (en) 1998-06-04 1998-07-29 Merck Sharp & Dohme Therapeutic compound
US6534651B2 (en) * 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
US6630490B2 (en) * 2000-07-07 2003-10-07 Neotherapeutics, Inc. Methods for treatment of disease-induced peripheral neuropathy and related conditions
US20020040032A1 (en) * 2000-07-07 2002-04-04 Glasky Michelle S. Methods for stimulation of synthesis of synaptophysin in the central nervous system
WO2002004449A2 (en) * 2000-07-07 2002-01-17 Neotherapeutics, Inc. Methods for treatment of conditions affected by activity of multidrug transporters
US20020040031A1 (en) * 2000-07-07 2002-04-04 Glasky Michelle S. Methods for prevention of accumulation of amyloid beta peptide in the central nervous system
US6770638B2 (en) * 2001-04-20 2004-08-03 Spectrum Pharmaceuticals, Inc. Tetrahydroindolone and purine derivatives linked to arylpiperazines
US6759427B2 (en) * 2001-04-20 2004-07-06 Spectrum Pharmaceuticals, Inc. Synthesis and methods of use of tetrahydroindolone analogues and derivatives
JP4964593B2 (ja) * 2003-09-25 2012-07-04 セノメド バイオサイエンシーズ，エルエルシー 神経学的病状の治療用のテトラヒドロインドロン誘導体

Also Published As

Publication number Publication date
ES2385932T3 (es) 2012-08-03
WO2002085856A1 (en) 2002-10-31
EP1383742A1 (de) 2004-01-28
US20030022892A1 (en) 2003-01-30
US6982269B2 (en) 2006-01-03
US20120070385A1 (en) 2012-03-22
DK1383742T3 (da) 2011-02-14
US8063233B2 (en) 2011-11-22
DE60238113D1 (de) 2010-12-09
EP1383742B1 (de) 2010-10-27
US20020198218A1 (en) 2002-12-26
US20090192319A1 (en) 2009-07-30
US6759427B2 (en) 2004-07-06
US8734818B2 (en) 2014-05-27
US20130225648A1 (en) 2013-08-29
US7531670B2 (en) 2009-05-12
US20050096317A1 (en) 2005-05-05
US8377456B2 (en) 2013-02-19

Similar Documents

Publication Publication Date Title
DE60238113D1 (de) Synthese und verfahren zu deren verwendung von tetrahydroindolon analogen und derivaten
ATE269295T1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
DE69829625D1 (de) Verfahren und Vorrichtung zur Behandlung von Perfluorokohlenstoff
DE10291574D2 (de) Vorrichtung und Verfahren zum katalytischen Reformieren von Kohlenwasserstoffen oder Alkoholen
DE60142410D1 (de) Immunomodulatorische polynukleotide und verfahren zur deren verwendung
ATE414089T1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
DE60027913D1 (de) 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz
ATE388135T1 (de) Verfahren zur herstellung von 1,3-substituierte indene und aryl-annellierte azapolycyclische verbindungen
DE60304109D1 (de) Verfahren zur Herstellung von Ringelementen und Vorrichtung zu dessen Durchführung
DE10107712B4 (de) Vorrichtung und Verfahren zur energetischen Nutzung von Faulschlammvergasungsgas
DE69936285D1 (de) INDOLOi2,1-BöQUINAZOLIN-6,12-DIONE ANTIMALARIA DERIVATE UND METHODEN ZUR BEHANDLUNG VON MALARIA
DE60043207D1 (de) Verfahren und Vorrichtung zur Reinigung von Gasen
DE59712772D1 (de) Verfahren zur fraktionierten Kristallisation von Substanzen, zur Durchführung des Verfahrens geeigneter Kristallisator, sowie Verwendung des Kristallisators
DE60024705D1 (de) Reaktionsvorrichtung zur Herstellung von Alkanolamin sowie Verfahren zur Alkanolaminherstellung mit Verwendung der Vorrichtung
DE60221462D1 (de) Vorrichtung und Verfahren zur High-Level Synthese, Verfahren zur Produktion von logischen Schaltungen unter Verwendung des Verfahrens zur High-Level Synthese und Aufzeichnungsmedium
DE60307830D1 (de) Neue multimerische moleküle, verfahren zu deren herstellung, und deren verwendung zur herstellung von arzneimitteln
DE60021960D1 (de) Verfahren zur Kompensation von Neigung und/oder Defokussierung, und Vorrichtung für dasselbige
DE50111926D1 (de) Strahlungsanordnung sowie deren Verwendung und Verfahren zur Behandlung von Oberflächen
ATE423110T1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
ATE522205T1 (de) Testosteronhaltiges transdermales therapeutisches system und verfahren zu seiner herstellung
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE60232696D1 (de) Verfahren und Vorrichtung zur Behandlung von Synthesegas und verwandten Gasen
DE60221275D1 (de) Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma
DE60223718D1 (de) Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen
ATE319668T1 (de) Verfahren zur synthese von (2s)-indolin-2- carbonsäure, und verwendung in der synthese von perindopril

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1383742

Country of ref document: EP